See if empagliflozin helps kidney function in people with lupus nephritis
Official title: Does The Positive Reno-Protective Effect Of Sodium Glucose Co-Transporter 2 Inhibitors Extend To Lupus Nephritis Population?
Run by Beni-Suef University · NCT07700940 · Data updated 2026-11-12
This study tests whether adding empagliflozin to standard care improves kidney function in adults with active lupus nephritis.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 66 (estimated) |
| Sponsor | Beni-Suef University Academic / other |
| Locations | 1 site (Banī Suwayf) |
| Status | Recruiting |
| Started | January 22, 2024 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | July 15, 2026 |
| Trial ID | NCT07700940 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with biopsy-proven active lupus nephritis (classes III, IV, or overlapping) and preserved kidney filtration (eGFR ≥ 30) with relatively high proteinuria (uPCR > 1000 mg/g).
✕Probably not a fit
Patients with diabetes, very low kidney function (eGFR < 30), or very low proteinuria may be less likely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 4 interventional trial evaluates the effect of empagliflozin (25 mg tablets) added to standard therapy compared with placebo and standard care in adults with biopsy-confirmed active lupus nephritis. Eligible participants have specific LN classes, an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m2, and a urinary protein creatinine ratio (uPCR) above 1000 mg/g. The study excludes those with diabetes, significant hepatic impairment, atrial fibrillation, and other comorbidities that could confound outcomes. Primary outcomes focus on kidney function and safety in this LN population, with empirical data from prior SGLT2 trials informing the rationale. Location is at Beni-Suef University Hospital in Banī Suwayf, Egypt, led by a sponsor with collaboration lacking external partners in this protocol.
Why it matters
Potential benefit: If successful, participants may experience better kidney function and reduced kidney-related complications.
How similar studies have gone: SGLT2 inhibitors have shown kidney benefits in other kidney disease and lupus contexts, but this exact LN population and off-label use require confirmation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥ 18 years) with established biopsy-proven LN of active III, IV, overlapping III/IV, or overlapping III/V classes. * eGFR ≥ 30 ml.min1.1.73m-2, * Urinary protein creatinine ratio (uPCR) \> 1000 mg/g. Exclusion Criteria: * Subjects with serious hypersensitivity (angioedema and/or anaphylaxis) to EMPA. * eGFR \< 30 ml.min-1.1.73m-2. * uPCR \< 1000 mg/g. * Type 1 or 2 diabetes. * Aterial fibrillation. * Hepatic impairment \[defined as alanine transaminase or aspartate transaminase \>3 times the upper limit of normal (ULN) or total bilirubin \>2 times the ULN at the time of enrolment\]. * Any condition outside the renal and cardiovascular study area with a life expectancy of \< 6 months based on care provider's clinical judgment. * Those who enrolled in an experimental study in the previous 6 months.
Where it's running
-
Beni-Suef university hospital
Banī Suwayf, Egypt Recruiting
Study contacts
- Study coordinator: Associate professor. Ahmed Yehia
- Email: ahmed_yehia@med.bsu.edu.eg
- Phone: +201090905827
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis
This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.
-
Lupus Nephritis Care Pathway
A small group of adults with lupus nephritis will try a team-based care path that uses telemedicine and pharmacist-led support to help manage their treatment and see if it improves adherence and outcomes.
-
Initial glucocorticoid-dose harmonization in childhood lupus nephritis
This trial tests whether starting children with Lupus Nephritis on a lower or higher prednisone dose makes a difference in treatment outcomes.
-
HB2198 for adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus
This trial will test whether two intravenous doses of HB2198 can safely reduce B cells and improve disease measures in adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus.
-
HSK39297 tablets for lupus nephritis
This trial will test whether once-daily oral HSK39297 (200 mg or 300 mg) is safe and well tolerated compared with placebo in adults with active lupus nephritis.
-
Comparing two biologic induction regimens and standard mycophenolate therapy for active proliferative lupus nephritis over six months
This trial will test whether biologic induction therapy with belimumab or telitacicept leads to better kidney responses over six months than standard mycophenolate-based treatment in people aged 14–65 with active proliferative lupus nephritis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.